Jordan Glasgow @JordanGlasgow00 from Tucker, GA will be completing his PGY-1 training at Wellstar Kennestone Regional Medical Center in Marietta, GA. Mentors: @blandman19 and @KerryWard10. Way to go Jordan! #UGAMatch2024
🥵 In ICH 1 mL hematoma expansion = 5% 🔼 in the odds of death or dependence!
A call to action to improve the care of pts with ICH by:
1⃣ Bundled care
2⃣ time-based metrics
An excellent review of the literature in ICH and what we can do moving forward:
https://t.co/HOzlsG63CX
So there used to be a dosing rec in Lexi for alteplase in acute hemody. unstable pts that was a 20mg bolus, with the remaining over 2 hours. It is no longer there and I can’t find any references for that dosing strategy? Does anyone know why it was removed/have a ref?
Some of the Anexxa-I results are out. Looks like excellent/good hemostasis was 64% vs 52% with Anexxa vs "usual care" but no difference in 30-day mortality or functional outcomes and higher VTE risk of 10% vs 6%.
Still want the full text....
So if you had an anticoagulant reversal medication that stopped hematoma expansion, but had no effect on 30-day outcomes, and had a 4x increased risk of ischemic stroke, would you give it?
#ANNEXa_I
Definitely was hoping for more of a wow factor after all the hype.
🤔 NO Difference in mortality or 30d outcomes
⬆️ TE events
-> no surprise AA significantly ⬇️ anti-FXa vs PCC
Would have loved to see a simultaneous publication… still waiting on the details 👀 #ANNEXAi#WSC2023
A key point in ACLS is that in shockable rhythms, the ⚡ is key to improving outcomes
A knee-jerk reaction in a code is to give epi, but epi before shock in a shockable rhythm WORSENS outcomes
⚡once, then ⚡ again, THEN give epi
https://t.co/tHsxNsKYBB
https://t.co/VAnNv7De81
Pleasure presenting our working comparing high- vs low-dose 4F-PCC for treating factor Xa-associated ICH. There was no evidence of a difference between 4F-PCC doses for heloststic effectiveness & no VTE events. @UConnPharmacy#ESCCongress#ESC2023
For those that made the switch from alteplase to tenecteplase for AIS, what was the biggest problem that you noticed that you didn’t anticipate? Doing a presentation on this soon and wanted to poll the masses.